Price$5.11+0.04 (+0.79%)
05:30 PM07:45 PM
News · 26 weeks49+29%
2026-04-192026-10-11
Mix2490d
- SEC Filings12(50%)
- Insider6(25%)
- Offering3(13%)
- Other2(8%)
- Earnings1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Aethlon Medical Inc.4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Aethlon Medical Inc.4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERAmendment: SEC Form 4/A filed by Aethlon Medical Inc.4/A - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Aethlon Medical Inc.4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Aethlon Medical Inc.4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Aethlon Medical Inc.4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- SECSEC Form 8-K filed by Aethlon Medical Inc.8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAmendment: SEC Form 8-K/A filed by Aethlon Medical Inc.8-K/A - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRFour High-Impact Small Caps Enter the SpotlightDENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The small-cap market is delivering a mix of catalysts, with the following companies in particular putting substantial new developments in front of investors: Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), and Turbo Energy (NASDAQ:TURB). Aethlon Medical: Radical Reset Puts NOR-101 in the Spotlight Aethlon Medical (NASDAQ:AEMD) is attempting one of the most dramatic strategic resets in this group, announcing a definitive all-stock merger with privately held North Immunology alongside an oversubscribed private placement expected to generate approximately $180 million. If completed,
- SECSEC Form 425 filed by Aethlon Medical Inc.425 - AETHLON MEDICAL INC (0000882291) (Subject)
- SECAethlon Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic DermatitisNorth Immunology's lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and non-type 2 inflammation, with the potential to deliver a best-in-disease treatment for patients with atopic dermatitisOversubscribed $180 million private placement is expected to fund the combined company's operations into the second half of 2028Phase 1a study of NOR-101 is expected to begin in the first quarter of 2027, with interim pharmacokinetic and safety data expected by mid-2027 and Phase 1b and Phase 2b topline data expected in 2028 SAN DIEGO and AUSTIN, Texas, Sept. 17, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD) ("Aethlon" or the
- SECAethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form DEF 14A filed by Aethlon Medical Inc.DEF 14A - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form 8-K filed by Aethlon Medical Inc.8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form PRE 14A filed by Aethlon Medical Inc.PRE 14A - AETHLON MEDICAL INC (0000882291) (Filer)
- PRPresenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live streamMIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Presenting Today – Wednesday August 19, 2026 8:30Virtual Lobby opens.Register for the Con
- PRPresenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live streamMIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Day 1 - WednesdayAugust 19, 2026 8:30Virtual Lobby opens.Register for the Conference. I
- SECSEC Form 10-Q filed by Aethlon Medical Inc.10-Q - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® ProgramConference Call Today at 4:30 p.m. ETSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal first quarter ended June 30, 2026, and provided a corporate update. "We advanced our clinical and research programs during the quarter," said James Frakes, CEO and CFO. "We treated the first participant in the third and final dosing cohort of our Phase 1 oncology study in Australia, and early biomarker signals from the initial cohorts support continuing evaluation of the Hemopurifier. We also had a Long COVID manuscript accepted for publication, which strengthens
- PRAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2026, at 4:15 p.m. ET on Thursday, August 13, 2026. Management will host a conference call on Thursday, August 13, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10211144/104a3acc428.
- SECAethlon Medical Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRPresenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live streamMIAMI, July 15, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 94th Emerging Growth Conference on July 15 & 16, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Presenting Today – Wednesday July 15, 2026 11:00Virtual Lobby opens.Register for the Conference. If you already registered
AEMD FAQ
6 questionsWhat does Aethlon Medical Inc. do?
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for...Where does AEMD stock trade?
Aethlon Medical Inc. (AEMD) is listed on NASDAQ.What sector and industry is AEMD in?
Aethlon Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about AEMD?
Aethlon Medical Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $150.00 price target on 2025-07-07.What companies are similar to AEMD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare AEMD side-by-side with any of them on Quantisnow.How can I track AEMD on Quantisnow?
Quantisnow aggregates Aethlon Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AEMD to receive live email and push alerts on every new disclosure.